The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Targeted molecular imaging agents (TMIAs) are derived from coupling together pre-formed amino acids with imaging agents attached to their side chains. These peptide-based imaging agents may synthesized from a single or multiple preformed amino acids containing multi-modal, multi-chelated metal, multi-dye imaging agents, or combinations of these, on the side chains of resultant peptides. These imaging amino acids or peptides may be conjugated directly, or activated, or attached to linkers to which targeting groups, such as peptides, proteins, antibodies, aptamers, or small molecule inhibitors, may be conjugated in the final steps of the synthesis to form a wide variety of TMIAs.

Novel crystalline porous materials known as metal-organic frameworks (MOFs) and methods for their synthesis are provided herein. The MOFs include a M.sub.6(.sub.3-OH).sub.8(OH).sub.8(.sup.2,.sup.2-(O.sub.2C).sub.2cyclam).sub.8 cluster, and a metal atom coordinated to the one or more cyclam of the cluster, wherein M is Zr or Hf, and the metal atom is any one of Cu, Ni, Cr, Ru, Co, and Gd. The MOFs can be used as an adsorbent, alone or in a medium with other components, of CO.sub.2. The MOFs can also be used as a catalyst for the transformation of CO.sub.2 and epoxides to cyclic carbonates. The MOFs can also be used in the electrochemical catalytic reduction of CO.sub.2. The MOFs can also be used for photocatalytic CO.sub.2 reduction for the production of carbon-based fossil fuels. The MOFs can also be used for light-induced nitric oxide (NO) release. The MOFs can also be used as magnetic resonance imaging (MRI) agents.

The present disclosure generally provides compounds useful as MRI contrast agents. In some aspects, the disclosure provides MRI contrast agents that are chemically modified to have one or more moieties that include hydrophobic portions. In some aspects, the disclosure provides compositions that include such modified MRI contrast agents and a protein, such as albumin or albumin mimetics. Further, the disclosure provides various uses of these compounds and compositions.

The present invention relates to new class of dimeric macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with the paramagnetic metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.

Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

The present disclosure relates to magnetic resonance imaging (MRI) methods comprising (i) obtaining a baseline chemical exchange saturation transfer (CEST) MRI image of a patient, (ii) administering an effective amount of a non-nutritive sweetener to the patient, and (iii) obtaining one or more test CEST MRI image of the patient subsequent to the administering step (ii); wherein the step (i) and (iii) acquisition parameters are substantially the same. The non-nutritive sweetener may include a natural or artificial sugar alcohol, polyol, or combinations or derivatives thereof.

The present disclosure relates to a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd.sup.3+ ion, and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.

Disclosed herein are complexes of gadolinium metal, ligand and meglumine that are substantially free of non-aqueous solvents. In particular, solvent-free complexes of 1) gadopentetate dimeglumine and 2) gadoterate meglumine are disclosed and methods of their preparation are disclosed. In addition, methods are disclosed for purifying reactants, monitoring and controlling pH, quantifying the free gadolinium content, quantifying the concentration of gadolinium-ligand complex in aqueous solution, and procedures for producing a drug product in one step. The one step process eliminates the need to dry the gadolinium-ligand complex, which is typically highly hygroscopic. The one step process includes purification steps that do not require the use of non-aqueous solvents.